

## Table of contents

<b>1</b>	<b>Diabetes Mellitus and the Normal Metabolic Pathways</b>	<b>6</b>
	<i>Definition</i>	6
	<i>Digestion and absorption</i>	8
	<i>Metabolism in the cell</i>	12
	<i>Intermediary metabolism of glucose</i>	15
	<i>The synthesis of fatty acids</i>	18
	<i>Ketone production</i>	19
<b>2</b>	<b>The Diabetic State and the Action of Insulin</b>	<b>21</b>
	<i>Insulin and glucose transport</i>	22
	<i>Insulin and lipid metabolism</i>	25
	<i>Insulin and protein metabolism</i>	27
	<i>The site of insulin action</i>	28
	<i>Other endocrine influences</i>	32
	<i>The pancreas and native insulin</i>	33
	<i>Orinase and native insulin release</i>	40
	<i>Similarity of effects of native insulin and Orinase</i>	46
	<i>Insulin production in the diabetic</i>	50
<b>3</b>	<b>Symptomatology Diagnosis and Complications of Diabetes</b>	<b>52</b>
	<i>Etiology</i>	52
	<i>Presenting symptoms and signs</i>	53
	<i>Laboratory diagnosis</i>	54
	<i>Complications or sequellae</i>	57
<b>4</b>	<b>Treatment of Diabetes Mellitus</b>	<b>60</b>
	<i>Treatment principles</i>	60
	<i>Factors affecting insulin requirements</i>	61
	<i>Dietary treatment</i>	65
	<i>Treatment with insulin</i>	70
	<i>Establishing the dose</i>	70
	<i>Insulin reactions: symptoms and treatment</i>	73
	<i>Complications of insulin therapy</i>	74
	<i>Treatment with oral antidiabetic agents</i>	75
	<i>The sulfonylureas</i>	75
	<i>Results of clinical trials with tolbutamide, Upjohn-Orinase®</i>	76
	<i>Advantages of Orinase over insulin</i>	76
	<i>Initiation of therapy with Orinase</i>	78
	<i>Transfer from treatment with insulin to Orinase</i>	79
	<i>Maintenance dose of Orinase</i>	79
	<i>Combined insulin and Orinase in treatment</i>	79
	<i>Other oral antidiabetic agents</i>	81
	<i>Biguanides in the treatment of diabetics</i>	84
	<i>Treatment with combined oral antidiabetic agents</i>	86
	<i>Treatment of ketoacidosis and diabetic coma</i>	86
<b>5</b>	<b>Pathology of Diabetes and Diabetic Angiopathy</b>	<b>90</b>
	<i>General pathologic changes in diabetes</i>	90
	<i>Abnormal glycogen deposition</i>	90
	<i>Pathologic changes in the pancreas</i>	91
	<i>Diabetic neuropathy</i>	96
	<i>Diabetic retinopathy</i>	97
	<i>Diabetic nephropathy</i>	105
	<i>Effect of new treatments on complications</i>	109
	<i>Looking forward</i>	110
	<b>The History of Diabetes</b>	<b>112</b>
	<b>Bibliography</b>	<b>116</b>
	<b>Acknowledgments and Index of Illustrations</b>	<b>116</b>
	<b>Metabolic Interrelationships: Supplement</b>	

**Fig. 1:** Section of normal human pancreas  
Differences in staining properties and arrangement are readily apparent between the enzyme-producing acinar cells and the central clump of islet cells (island of Langerhans). Variation in the nuclei indicates that the islets are composed of several types of cell, one of which produces insulin. (Hematoxylin and eosin stain)